4mq2 - Revision history

OCA at 16:40, 20 September 2023

OCA — Wed, 20 Sep 2023 16:40:27 GMT

←Older revision		Revision as of 16:40, 20 September 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4mq2]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MQ2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4MQ2 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4mq2]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MQ2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4MQ2 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1PE:PENTAETHYLENE+GLYCOL'>1PE</scene>, <scene name='pdbligand=2C4:METHYL+4-CHLORO-3-{[(2-METHOXY-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-6-YL)CARBONYL]AMINO}BENZOATE'>2C4</scene>, <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.8Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1PE:PENTAETHYLENE+GLYCOL'>1PE</scene>, <scene name='pdbligand=2C4:METHYL+4-CHLORO-3-{[(2-METHOXY-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-6-YL)CARBONYL]AMINO}BENZOATE'>2C4</scene>, <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4mq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mq2 OCA], [https://pdbe.org/4mq2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4mq2 RCSB], [https://www.ebi.ac.uk/pdbsum/4mq2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4mq2 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4mq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mq2 OCA], [https://pdbe.org/4mq2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4mq2 RCSB], [https://www.ebi.ac.uk/pdbsum/4mq2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4mq2 ProSAT]</span></td></tr>
	</table>		</table>
Line 20:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 4mq2" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4mq2" style="background-color:#fffaf0;"></div>
-
-	==See Also==
-	*[[Dual specificity tyrosine-phosphorylation-regulated kinase\|Dual specificity tyrosine-phosphorylation-regulated kinase]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 10:00, 28 December 2022

OCA — Wed, 28 Dec 2022 10:00:36 GMT

←Older revision		Revision as of 10:00, 28 December 2022
Line 1:		Line 1:

	==The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor==		==The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor==
-	<StructureSection load='4mq2' size='340' side='right' caption='[[4mq2]], [[Resolution\|resolution]] 2.80Å' scene=''>	+	<StructureSection load='4mq2' size='340' side='right'caption='[[4mq2]], [[Resolution\|resolution]] 2.80Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4mq2]] is a 4 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MQ2 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4MQ2 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4mq2]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MQ2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4MQ2 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1PE:PENTAETHYLENE+GLYCOL'>1PE</scene>, <scene name='pdbligand=2C4:METHYL+4-CHLORO-3-{[(2-METHOXY-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-6-YL)CARBONYL]AMINO}BENZOATE'>2C4</scene>, ~~<scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1PE:PENTAETHYLENE+GLYCOL'>1PE</scene>, <scene name='pdbligand=2C4:METHYL+4-CHLORO-3-{[(2-METHOXY-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-6-YL)CARBONYL]AMINO}BENZOATE'>2C4</scene>, <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-	~~<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat">~~<scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene>~~</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4mq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mq2 OCA], [https://pdbe.org/4mq2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4mq2 RCSB], [https://www.ebi.ac.uk/pdbsum/4mq2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4mq2 ProSAT]</span></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2vx3\|2vx3]]~~, ~~[[4mq1\|4mq1]]~~<~~/td></tr>~~	+
-	~~<tr id~~='~~gene'><td class~~=~~"sblockLbl"><b>[[Gene\|Gene~~:~~]]</b></td><td class="sblockDat">DYRK1A, DYRK, MNB, MNBH ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>~~	+
-	~~<tr id='activity~~'>~~<td class="sblockLbl"><b>Activity:~~</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Dual-specificity_kinase Dual-specificity kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.12.1 2.7.12.1] </span></td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4mq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mq2 OCA], [~~http~~://pdbe.org/4mq2 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4mq2 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4mq2 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4mq2 ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/DYR1A_HUMAN DYR1A_HUMAN]] Defects in DYRK1A are the cause of mental retardation autosomal dominant type 7 (MRD7) [MIM:[~~http~~://omim.org/entry/614104 614104]]. A disease characterized by primary microcephaly, severe mental retardation without speech, anxious autistic behavior, and dysmorphic features, including bitemporal narrowing, deep-set eyes, large simple ears, and a pointed nasal tip. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period.<ref>PMID:21294719</ref>	+	[https://www.uniprot.org/uniprot/DYR1A_HUMAN DYR1A_HUMAN] Defects in DYRK1A are the cause of mental retardation autosomal dominant type 7 (MRD7) [MIM:[https://omim.org/entry/614104 614104]. A disease characterized by primary microcephaly, severe mental retardation without speech, anxious autistic behavior, and dysmorphic features, including bitemporal narrowing, deep-set eyes, large simple ears, and a pointed nasal tip. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period.<ref>PMID:21294719</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/DYR1A_HUMAN DYR1A_HUMAN]] May play a role in a signaling pathway regulating nuclear functions of cell proliferation. Phosphorylates serine, threonine and tyrosine residues in its sequence and in exogenous substrates.<ref>PMID:8769099</ref>	+	[https://www.uniprot.org/uniprot/DYR1A_HUMAN DYR1A_HUMAN] May play a role in a signaling pathway regulating nuclear functions of cell proliferation. Phosphorylates serine, threonine and tyrosine residues in its sequence and in exogenous substrates.<ref>PMID:8769099</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 24:		Line 20:
	</div>		</div>
	<div class="pdbe-citations 4mq2" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4mq2" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Dual specificity tyrosine-phosphorylation-regulated kinase\|Dual specificity tyrosine-phosphorylation-regulated kinase]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Dual-specificity kinase~~]]	+	[[Category: Homo sapiens]]
-	[[Category: ~~Human~~]]	+	[[Category: Large Structures]]
-	[[Category: Garvie, C]]	+	[[Category: Garvie C]]
-	[[Category: Janson~~, C A~~]]	+	[[Category: Janson CA]]
-	[[Category: Liang, L]]	+	[[Category: Liang L]]
-	[[Category: Lukacs~~, C M]]~~	+	[[Category: Lukacs CM]]
-	~~[[Category: Dyrk1a]]~~	+
-	~~[[Category: Dyrk1b]]~~	+
-	~~[[Category: Kinase]]~~	+
-	~~[[Category: Transferase-transferase inhibitor complex~~]]	+

OCA at 07:22, 4 August 2016

OCA — Thu, 04 Aug 2016 07:22:02 GMT

←Older revision		Revision as of 07:22, 4 August 2016
Line 1:		Line 1:
		+
	==The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor==		==The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor==
	<StructureSection load='4mq2' size='340' side='right' caption='[[4mq2]], [[Resolution\|resolution]] 2.80Å' scene=''>		<StructureSection load='4mq2' size='340' side='right' caption='[[4mq2]], [[Resolution\|resolution]] 2.80Å' scene=''>
Line 8:		Line 9:
	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">DYRK1A, DYRK, MNB, MNBH ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>		<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">DYRK1A, DYRK, MNB, MNBH ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Dual-specificity_kinase Dual-specificity kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.12.1 2.7.12.1] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Dual-specificity_kinase Dual-specificity kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.12.1 2.7.12.1] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mq2 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4mq2 RCSB], [http://www.ebi.ac.uk/pdbsum/4mq2 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mq2 OCA], [http://pdbe.org/4mq2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4mq2 RCSB], [http://www.ebi.ac.uk/pdbsum/4mq2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4mq2 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 22:		Line 23:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4mq2" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 16:20, 21 December 2014

OCA — Sun, 21 Dec 2014 16:20:35 GMT

←Older revision		Revision as of 16:20, 21 December 2014
Line 1:		Line 1:
-	~~{{STRUCTURE_4mq2\| PDB=4mq2 \| SCENE= }}~~	+	==The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor==
-	===The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor===	+	<StructureSection load='4mq2' size='340' side='right' caption='[[4mq2]], [[Resolution\|resolution]] 2.80Å' scene=''>
-	{~~{ABSTRACT_PUBMED_24239188}~~}	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[4mq2]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MQ2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4MQ2 FirstGlance]. <br>
-	==Disease==	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1PE:PENTAETHYLENE+GLYCOL'>1PE</scene>, <scene name='pdbligand=2C4:METHYL+4-CHLORO-3-{[(2-METHOXY-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-6-YL)CARBONYL]AMINO}BENZOATE'>2C4</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
		+	<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2vx3\|2vx3]], [[4mq1\|4mq1]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">DYRK1A, DYRK, MNB, MNBH ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Dual-specificity_kinase Dual-specificity kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.12.1 2.7.12.1] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mq2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mq2 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4mq2 RCSB], [http://www.ebi.ac.uk/pdbsum/4mq2 PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
	[[http://www.uniprot.org/uniprot/DYR1A_HUMAN DYR1A_HUMAN]] Defects in DYRK1A are the cause of mental retardation autosomal dominant type 7 (MRD7) [MIM:[http://omim.org/entry/614104 614104]]. A disease characterized by primary microcephaly, severe mental retardation without speech, anxious autistic behavior, and dysmorphic features, including bitemporal narrowing, deep-set eyes, large simple ears, and a pointed nasal tip. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period.<ref>PMID:21294719</ref>		[[http://www.uniprot.org/uniprot/DYR1A_HUMAN DYR1A_HUMAN]] Defects in DYRK1A are the cause of mental retardation autosomal dominant type 7 (MRD7) [MIM:[http://omim.org/entry/614104 614104]]. A disease characterized by primary microcephaly, severe mental retardation without speech, anxious autistic behavior, and dysmorphic features, including bitemporal narrowing, deep-set eyes, large simple ears, and a pointed nasal tip. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period.<ref>PMID:21294719</ref>
-		+	== Function ==
-	==Function==	+
	[[http://www.uniprot.org/uniprot/DYR1A_HUMAN DYR1A_HUMAN]] May play a role in a signaling pathway regulating nuclear functions of cell proliferation. Phosphorylates serine, threonine and tyrosine residues in its sequence and in exogenous substrates.<ref>PMID:8769099</ref>		[[http://www.uniprot.org/uniprot/DYR1A_HUMAN DYR1A_HUMAN]] May play a role in a signaling pathway regulating nuclear functions of cell proliferation. Phosphorylates serine, threonine and tyrosine residues in its sequence and in exogenous substrates.<ref>PMID:8769099</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	DYRK1B is a kinase over-expressed in certain cancer cells (including colon, ovarian, pancreatic, etc.). Recent publications have demonstrated inhibition of DYRK1B could be an attractive target for cancer therapy. From a data-mining effort, the team has discovered analogues of pyrido[2,3-d]pyrimidines as potent enantio-selective inhibitors of DYRK1B. Cells treated with a tool compound from this series showed the same cellular effects as down regulation of DYRK1B with siRNA. Such effects are consistent with the proposed mechanism of action. Progress of the SAR study is presented.

-	~~==About this Structure==~~	+	Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.,Anderson K, Chen Y, Chen Z, Dominique R, Glenn K, He Y, Janson C, Luk KC, Lukacs C, Polonskaia A, Qiao Q, Railkar A, Rossman P, Sun H, Xiang Q, Vilenchik M, Wovkulich P, Zhang X Bioorg Med Chem Lett. 2013 Dec 15;23(24):6610-5. doi: 10.1016/j.bmcl.2013.10.055., Epub 2013 Nov 1. PMID:24239188<ref>PMID:24239188</ref>
-	[~~[4mq2]~~] is a ~~4 chain structure~~. ~~Full crystallographic information is available from [http~~:/~~/oca~~.~~weizmann~~.ac.~~il/oca-bin/ocashort?id=4MQ2 OCA]~~.	+

-	==~~Reference~~==	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~<ref group="xtra">PMID:024239188</ref>~~<references ~~group="xtra"~~/><~~references~~/>	+	</div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
	[[Category: Dual-specificity kinase]]		[[Category: Dual-specificity kinase]]
-	[[Category: Garvie, C.]]	+	[[Category: Human]]
-	[[Category: Janson, C A.]]	+	[[Category: Garvie, C]]
-	[[Category: Liang, L.]]	+	[[Category: Janson, C A]]
-	[[Category: Lukacs, C M.]]	+	[[Category: Liang, L]]
		+	[[Category: Lukacs, C M]]
	[[Category: Dyrk1a]]		[[Category: Dyrk1a]]
	[[Category: Dyrk1b]]		[[Category: Dyrk1b]]
	[[Category: Kinase]]		[[Category: Kinase]]
	[[Category: Transferase-transferase inhibitor complex]]		[[Category: Transferase-transferase inhibitor complex]]

OCA at 13:36, 11 December 2013

OCA — Wed, 11 Dec 2013 13:36:29 GMT

←Older revision		Revision as of 13:36, 11 December 2013
Line 1:		Line 1:
-	~~'''Unreleased~~ structure~~'''~~	+	{{STRUCTURE_4mq2\| PDB=4mq2 \| SCENE= }}
		+	===The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor===
		+	{{ABSTRACT_PUBMED_24239188}}

-	~~The~~ entry ~~4mq2~~ is ~~ON HOLD~~	+	==Disease==
		+	[[http://www.uniprot.org/uniprot/DYR1A_HUMAN DYR1A_HUMAN]] Defects in DYRK1A are the cause of mental retardation autosomal dominant type 7 (MRD7) [MIM:[http://omim.org/entry/614104 614104]]. A disease characterized by primary microcephaly, severe mental retardation without speech, anxious autistic behavior, and dysmorphic features, including bitemporal narrowing, deep-set eyes, large simple ears, and a pointed nasal tip. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period.<ref>PMID:21294719</ref>

-	~~Authors~~: ~~Lukacs, C~~.M.~~, Janson, C.A~~., ~~Garvie, C., Liang, L~~.	+	==Function==
		+	[[http://www.uniprot.org/uniprot/DYR1A_HUMAN DYR1A_HUMAN]] May play a role in a signaling pathway regulating nuclear functions of cell proliferation. Phosphorylates serine, threonine and tyrosine residues in its sequence and in exogenous substrates.<ref>PMID:8769099</ref>

-	~~Description: The crystal structure of DYRK1a with~~ a ~~bound pyrido~~[~~2,3~~-d]~~pyrimidine~~ inhibitor	+	==About this Structure==
		+	[[4mq2]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MQ2 OCA].
		+
		+	==Reference==
		+	<ref group="xtra">PMID:024239188</ref><references group="xtra"/><references/>
		+	[[Category: Dual-specificity kinase]]
		+	[[Category: Garvie, C.]]
		+	[[Category: Janson, C A.]]
		+	[[Category: Liang, L.]]
		+	[[Category: Lukacs, C M.]]
		+	[[Category: Dyrk1a]]
		+	[[Category: Dyrk1b]]
		+	[[Category: Kinase]]
		+	[[Category: Transferase-transferase inhibitor complex]]

OCA: Protected "4mq2" [edit=sysop:move=sysop]

OCA — Sun, 29 Sep 2013 07:40:43 GMT

Protected "4mq2" [edit=sysop:move=sysop]

←Older revision

Revision as of 07:40, 29 September 2013

OCA: New page: '''Unreleased structure''' The entry 4mq2 is ON HOLD Authors: Lukacs, C.M., Janson, C.A., Garvie, C., Liang, L. Description: The crystal structure of DYRK1a with a bound pyrido[2,3-d]p...

OCA — Sun, 29 Sep 2013 07:40:42 GMT

New page: '''Unreleased structure''' The entry 4mq2 is ON HOLD Authors: Lukacs, C.M., Janson, C.A., Garvie, C., Liang, L. Description: The crystal structure of DYRK1a with a bound pyrido[2,3-d]p...

New page

'''Unreleased structure'''

The entry 4mq2 is ON HOLD

Authors: Lukacs, C.M., Janson, C.A., Garvie, C., Liang, L.

Description: The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor